bioXXmed AG (FRA:T5O)

bioXXmed AG Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	0.02	0	0.02	0.01	0.04
Revenue Growth (YoY)	378.99%	-79.93%	42.27%	-72.59%	23.96%
Gross Profit	0.02	0	0.02	0.01	0.04
Selling, General & Admin	0.03	0.01	0.01	0	0.55
Other Operating Expenses	0.26	0.86	0.82	0.83	1.01
Operating Expenses	0.29	0.88	0.82	0.84	1.61
Operating Income	-0.27	-0.87	-0.81	-0.82	-1.57
Interest Expense	-0.01	-	-	-0.04	-0
Interest & Investment Income	0	-	0.02	0.03	0
Other Non Operating Income (Expenses)	0.01	0	-	-	-
EBT Excluding Unusual Items	-0.27	-0.87	-0.79	-0.83	-1.57
Gain (Loss) on Sale of Investments	-0.1	-0.13	-20.16	-	-2.49
Pretax Income	-0.37	-1	-20.95	-0.83	-4.06
Income Tax Expense	-0	-	-	-	-
Net Income	-0.37	-1	-20.95	-0.83	-4.06
Net Income to Common	-0.37	-1	-20.95	-0.83	-4.06
Shares Outstanding (Basic)	0	0	0	0	0
Shares Outstanding (Diluted)	0	0	0	0	0
Shares Change (YoY)	-	164.59%	-	27.54%	-
EPS (Basic)	-1.34	-3.67	-203.88	-8.08	-50.38
EPS (Diluted)	-1.34	-3.67	-203.88	-8.08	-50.38
Free Cash Flow	-0.34	-0.92	-0.73	-0.91	-
Free Cash Flow Per Share	-1.23	-3.37	-7.11	-8.90	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-1621.11%	-24950.87%	-4633.08%	-6727.67%	-3516.49%
Profit Margin	-2183.91%	-28540.14%	-120369.63%	-6783.58%	-9095.43%
Free Cash Flow Margin	-2002.27%	-26223.88%	-4194.44%	-7473.42%	-
EBITDA	-0.27	-0.87	-0.81	-0.82	-1.55
D&A For EBITDA	0	0	0	0.01	0.02
EBIT	-0.27	-0.87	-0.81	-0.82	-1.57

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 14, 2026

Data Sources Report a data error